Lantheus to release SPLASH trial data in Oct 2024 after 75% OS events reached

Lantheus Holdings, Inc.

Expects to release Phase 3 SPLASH data in October 2024 for 177Lu-PNT2002 in PSMA-expressing mCRPC.
Release triggered by reaching 75% of protocol-specified target overall survival events.
Trial randomized 412 patients 2:1; 84.6% of control arm crossed over to PNT2002.
Primary endpoint is radiographic progression-free survival; 80% of patients from North America.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.